Mohamed, AbdallaSun, CongshanDe Mello, VanessaSelfe, JoannaMissiaglia, EdoardoShipley, JanetMurray, Graeme I.Zammit, Pete S.Wackerhage, Henning2016-09-232016-09-232016-09Mohamed, A, Sun, C, De Mello, V, Selfe, J, Missiaglia, E, Shipley, J, Murray, G I, Zammit, P S & Wackerhage, H 2016, 'The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma', The Journal of pathology, vol. 240, no. 1, pp. 3-14. https://doi.org/10.1002/path.47450022-3417ORCID: /0000-0003-3981-2420/work/76973508http://hdl.handle.net/2164/7510Acknowledgements This study was funded by Sarcoma UK, Friends of Anchor and the Medical Research Council grant number 99477 awarded to HW and PSZ. This work was also supported, in part, by NHS funding to the NIHR Biomedical Research Centre at the Royal Marsden Hospital and the Institute of Cancer Research, and the Chris Lucas Trust, UK. We also thank the CCLG (Children's cancer and leukaemia group) Tissue Bank for access to samples, and contributing CCLG centres, including members of the ECMC paediatric network. The CCLG Tissue Bank is funded by Cancer Research UK and CCLG. The Zammit lab is also currently supported by Muscular Dystrophy UK (RA3-3052), Association Française Contre les Myopathies (17865, 20082, 19105 and 16050) and the FSH (Fascioscapulohumeral muscular dystrophy) Society (Shack Family and Friends research grant (FSHS-82013-06)). In addition, we would like to thank Prof Kun-Liang Guan and Prof Malcolm Logan for kindly providing constructs.125913901engSDG 3 - Good Health and Well-beinghippo pathwayTAZWWTR1embryonal rhabdomyosarcomamyoblastsR MedicineMedical Research Council (MRC)99477RJournal article10.1002/path.47452401